19th May 2025 19:54
AstraZeneca PLC - Cambridge-based pharmaceutical and biotechnology company - Phase 3b Batura trial shows statistically significant and clinically meaningful improvements in mild asthma in patients treated with Airsupra (albuterol and budesonide) than albuterol alone. Compared to placebo, Airsupra significantly reduces the risk of a severe symptom exacerbation by 47%. Patients treated with airsupra have 63% lower exposure to total systemic corticosteroids over the treatment period compared with albuterol-alone, reducing risks from cumulative exposure to SCS which include type 2 diabetes, depression and anxiety, renal impairment, cataracts, cardiovascular disease, pneumonia and fractures. Read More